AsiaIPEX is a one-stop-shop for players in the IP industry, facilitating IP trade and connection to the IP world. Whether you are a patent owner interested in selling your IP, or a manufacturer looking to buy technologies to upgrade your operation, you will find the portal a useful resource.

Back to search results

Novel Compositions for Cancer Therapy (Proteasomes Inhibitors)

Technology Benefits: Simple synthesis Unique structure differentiate claimed compositions from other, known compositions of matter in vitro, in vivo and clinical studies Potent activity with low cytotoxicity Mechanism of action well understood through

Technology Application: While most enabled for the treatment of diverse cancers e.g., myeloma, denocarcinoma, pancreatic cancer, B cell-related cancer and lymphomas, proteasomes inhibitors have also demonstrated utility for the treatment of diverse human diseases, including but not limited to retroviral infections such as human immunodeficiency virus-1 (HIV-1) infection, immune disorders, inflammation (epoxomicin), Stroke and neurodegenerative disease (via promotion of neurite outgrowth as described for lactacystin, omurolide, tyropeptin A, curcumin, capsaicin, and TMC-95A).

Detailed Technology Description: Within mammalian cells, proteasome inhibitors block the ability of proteasomes to degrade unneeded or damaged proteins. When administered, proteasome inhibitors have been shown to be effective for treatment of cancer, HIV infection and autoimmune diseases. UC inventors have isolated, characterized and synthesized a natural proteasome inhibitor, discovered from a tropical marine cyanobacteria. Proprietary compositions (parent and analogs), which have intriguing and unique structural features, are claimed for treatment of cancer and other diseases responsive to proteasome inhibition.

Industry: Disease Diagnostic/Treatment

Sub Category: HIV

Application No.: 9409944

Others

State Of Development

Assay-guided purification was used to identify and isolate the parent compounds, carmaphycins A and B work has demonstrated potent efficacy vs. human lung adenocarcinoma and colon cancer cells. The structures were elucidated by means of NMR and HRESIMS data and absolute and relative configurations were determined by total synthesis. A straightforward synthetic method has generated material sufficient to support in vivo assessment of efficacy of compositions.

Intellectual Property Info

Worldwide rights available; pending patents available under confidentiality.

Related Materials

Pereira, AR, et al., The Carmaphycins: New Proteasome Inhibitors Exhibiting an a, ß-Epoxyketone Warhead from a Marine Cyanobacterium
Inventor's Bio
Inventor information

Additional Technologies by these Inventors

Tech ID/UC Case

22376/2011-354-0

Related Cases

2011-354-0, 2010-351-0

*Abstract: Medicinal chemistry programs based on natural product leads have generated a large number of synthetic analogues optimized for therapeutic use. The most successful example may be Carfilzomib, inspired in the natural product epoxomicin and currently in phase III clinical trials for multiple myeloma. The promise of proteasome inhibitors is validated by the first-in-class approved drug, Velcade as well as numerous proteasome inhibitors in clinical trials.

*IP Issue Date: Aug 9, 2016

*Principal Investigator: Name: Tara Byrum
Department:

Name: Hosana Debonsi
Department:

Name: Andrew Fenley
Department:

Name: William Gerwick
Department:

Name: Michael Gilson
Department:

Name: Andrew Kale
Department:

Name: Bradley Moore
Department:

Name: Alban Pereira
Department:

Name: Fred Valeriote
Department:

Country/Region: USA

For more information, please click Here